Suboptimal peak inspiratory flow rate in dry-powder inhaler users for chronic obstructive pulmonary disease in Korea

Pulmonary Pharmacology and Therapeutics · Published 2024-04-10 · DOI 10.1016/j.pupt.2024.102298

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.pupt.2024.102298

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2024

Related articles

• Letter: Impact of Suboptimal Peak Inspiratory Flow on Exacerbations in Chronic Obstructive Pulmonary Disease Patients Using Dry Powder Inhalers · Journal of Aerosol Medicine and Pulmonary Drug Delivery · 2026 · Cites or is cited by this article
• Evaluation of the effect of modulator therapies on medication complexity in adult cystic fibrosis patients · Pulmonary Pharmacology and Therapeutics · 2026 · Same journal
• Prevalence and clinical significance of pre- and post-bronchodilator airflow obstruction in COPD patients · Pulmonary Pharmacology and Therapeutics · 2024 · Same journal
• Drug-drug interactions in vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor-ivacaftor · Pulmonary Pharmacology and Therapeutics · 2025 · Same journal
• Effects of EP395, a novel macrolide, on acute neutrophilic airway inflammation · Pulmonary Pharmacology and Therapeutics · 2025 · Same journal
• Effect of EP395, a novel anti-inflammatory macrolide, in an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial · Pulmonary Pharmacology and Therapeutics · 2025 · Same journal
• Synergistic induction of apoptosis in lung cancer cells via TOP2A targeting through combined dihydroartemisinin and chrysin treatment · Pulmonary Pharmacology and Therapeutics · 2026 · Same journal
• Clinical remission at two years post-diagnosis of asthma and its association with clinical outcomes: A retrospective cohort study in asthma patients with maintenance inhaler therapy · Pulmonary Pharmacology and Therapeutics · 2025 · Same journal
• m6A reader IGF2BP2 Mediates Airway Remodeling by Stabilizing Dixdc1 in Asthma Pathogenesis · Pulmonary Pharmacology and Therapeutics · 2026 · Same journal
• Effects of anumigilimab, an anti–G-CSF receptor mAb, after segmental LPS challenge: A Phase 1b trial in healthy volunteers · Pulmonary Pharmacology and Therapeutics · 2026 · Same journal